InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,187.70
(
0.13%
)
US TECH 100
17,614.80
(
0.01%
)
Dow Jones
38,884.26
(
0.08%
)
Brent Oil
81.68
(
-1.44%
)
Bitcoin
62,193.62
(
-0.23%
)
Post# of 251748
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119591
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Thursday, 06/12/2008 5:00:59 AM

Thursday, June 12, 2008 5:00:59 AM

Post# of 251748
MNTA has filled the open slot on the BoD from the
previously announced resignation of venture capitalist,
Stephen Reeders (#msg-28562403). The new director,
James Sulat, is the CFO of Memory Pharmaceuticals.
Sulat has a finance and management background with
degrees from Yale and Stanford.

http://biz.yahoo.com/pz/080611/144416.html

>>
Momenta Pharmaceuticals Announces Appointment of James R. Sulat to Board of Directors

Wednesday June 11, 8:00 am ET

CAMBRIDGE, Mass., June 11, 2008 (PRIME NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NasdaqGM: MNTA ), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of James R. Sulat, Chief Financial Officer and Director of Memory Pharmaceuticals Corp., to its Board of Directors effective June 5, 2008.

James R. Sulat has served as the Chief Financial Officer of Memory Pharmaceuticals since February 2008 and previously served as Memory Pharmaceuticals' President and Chief Executive Officer from May 2005 until February 2008. Jim has also served as a member of the board of directors of Memory Pharmaceuticals since May 2005. From May 2003 to February 2004, Mr. Sulat served as the Senior Executive Vice President of Moore Wallace Incorporated. Following the acquisition of Moore Wallace by R.R. Donnelley & Sons Company in February 2004, Mr. Sulat became Chief Financial Officer of R.R. Donnelley and served in that position until May 2004. From 1998 to 2003, Mr. Sulat served as Vice President and Chief Financial Officer of Chiron Corporation. Mr. Sulat serves as a director of Maxygen, Inc. and Intercell AG.

``We are very pleased that Jim has joined our Board of Directors. Jim brings extensive expertise in finance and general management as well as board experience. His strategic insights in both large and small biotechnology companies will be invaluable as we grow our organization,' stated Craig Wheeler, President and Chief Executive Officer of Momenta.

``I am delighted to be joining the board of Momenta at such an exciting time for the company, as M-Enoxaparin moves forward through the ANDA process, and as the company applies its proprietary technology to complex generics, follow-on biologics and novel drugs,' said Mr. Sulat. ``I look forward to contributing to these efforts.'

Mr. Sulat received a B.S. in Administrative Sciences from Yale University, and an M.B.A. and an M.S. in Health Services Administration from Stanford University.
<<


Let’s talk biotech!
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up